Enhanced Oncolytic Virus Growth Method and Antitumor Agent

The present inventive concept relates to a novel antitumor therapy using oncolytic viruses, specifically enhancing the antitumor effect of coxsackievirus through combination chemotherapy and optimized virus receptor expression.

The original patent disclosed a method for enhancing an antitumor effect of a coxsackievirus by administering oxaliplatin and the coxsackievirus to a subject in need thereof. However, the original method has limitations in terms of efficacy and resistance to oxaliplatin. The present inventive concept addresses these limitations by introducing combination chemotherapy and optimized virus receptor expression to enhance the antitumor effect of coxsackievirus.

The present inventive concept comprises methods for enhancing an antitumor effect of a coxsackievirus, promoting proliferation of a coxsackievirus, and enhancing an expression of a virus receptor of a cancer cell. The methods involve administering a combination of oxaliplatin and a second chemotherapeutic agent, culturing the coxsackievirus in the presence of a proteasome inhibitor, and administering a histone deacetylase inhibitor. The inventive concept also includes a system for treating oxaliplatin-resistant cancer comprising a coxsackievirus, an antimetabolite, and a third chemotherapeutic agent.

The present inventive concept introduces novel combinations of chemotherapeutic agents and optimized virus receptor expression, which are not obvious from the original patent. The use of a second chemotherapeutic agent, proteasome inhibitor, and histone deacetylase inhibitor in combination with oxaliplatin and coxsackievirus provides a synergistic effect in enhancing the antitumor effect of coxsackievirus.

Alternative embodiments of the inventive concept may include using different combinations of chemotherapeutic agents, varying the sequence and timing of administration, and incorporating additional agents to enhance the antitumor effect. Variations of the system for treating oxaliplatin-resistant cancer may include using different types of viruses, antimetabolites, and chemotherapeutic agents.

The present inventive concept has potential commercial applications in the development of novel antitumor therapies, particularly for treating oxaliplatin-resistant cancer. The target market includes pharmaceutical companies, research institutions, and hospitals specializing in cancer treatment.